Funded by NIH R01-GM073082, a novel computational method based on free energy decomposition and an iterative self-consistent reconstitution involving network rigidity to account for non-additivity in conformational entropy due to correlated motions has been developed. The program, FAST, provides a Flexibility And Stability Test for proteins that quantifies stability/flexibility relationships for understanding function. Speed versus accuracy is optimized for high-throughput screening to test for structure/function relationships in mutation studies, substrate binding, pKa predictions, allostery, protein-protein interactions and protein formulation.
8:55 Predicting Selectivity and Druggability in Small Molecule Drug Discovery
Alan Cheng, Ph.D., Senior Scientist, Chemistry Research & Development, Amgen, Inc. Structure-based druggability and selectivity analyses increasingly inform target assessment and setting of lead optimization strategies in drug discovery. Continuing work on druggability prediction will be presented in the context of applying druggability prediction approaches to large numbers of protein structures. Work on selectivity analysis will be presented in the context of kinase inhibitor discovery examples from Amgen, and we will show how a thermodynamics-based selectivity index can help in predicting biological selectivity. 
D., Senior Principal Systems Engineer, Boehringer Ingelheim GmbH
A robust and extensible web services framework for the delivery of computational properties to the medicinal chemist's desktop will be presented. This architecture fully leverages our High Performance Compute environment, exposes a wide variety of computational engines, and can be utilized in a manner that best fits the scientists' requirements. Use cases including the consumption of in silico physicochemical properties and the distribution of quantitative structure-activity relationship (QSAR) models will be described. Nucleo-cytoplasmic transport of macromolecules is a fundamental process of eukaryotic cells. Translocation of proteins and many RNAs between the nucleus and the cytoplasm is carried out by shuttling import and export receptors. CRM1 (Xpo1) is a major exporter for proteins from the nucleus to the cytoplasm, including tumor suppressors (TSPs) and other growth regulatory proteins (GRPs). Here, we describe the identification of novel Crm1 inhibitors using computational, hierarchical structure-based discovery process.
FREE ENERGY APPROACH TO STRUCTURE-BASED DRUG DESIGN

10:35
Networking Coffee Break in the Exhibit Hall with Poster Viewing » KEYNOTE PRESENTATION
11:00 Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine
David E. Shaw, Ph.D., Chief Scientist, D. E. Shaw Research and Senior Research Fellow, Center for Computational Biology and Bioinformatics, Columbia University Molecular dynamics simulation provides a potentially powerful tool for understanding the behavior of proteins at an atomic level of detail, but its relevance to drug design has previously been limited in part by the computational demands of such simulations. We have constructed a specialized supercomputer, called Anton, that has simulated the behavior of a number of proteins for periods as long as a millisecond --approximately 100 times the length of the longest such simulation previously published --revealing pharmaceutically relevant aspects of protein dynamics that were previously inaccessible to both computational and experimental study. The recent structures of GPCRs give us a better understanding of the binding pockets for both antagonist and agonists and insights into the structural mechanism of the receptor activation. Computational approaches to structurebased docking and modeling of pockets of subtypes and homologues are presented along with successful application of these methods to finding and optimizing GPCR modulators. Results of the recent docking and modeling assessment (a.k.a. GPCR Dock 2010) for CXCR4 with small molecule and a peptide, as well as the dopamine receptor D3, are reviewed.
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The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people you want to meet. This online system was designed with your privacy in mind and is available only to registered session attendees of this event. Registered conference attendees will receive more information on accessing the Intro-Net in the weeks leading up to the event! Lead Sponsoring Publications:
Web Partners:
ExhIbIT & SPONSORShIP OPPORTuNITIES
Structure-Based Drug Design presents your company with the opportunity to network with decision-makers and leading professionals from throughout the biopharmaceutical community. By participating as a Sponsor and Exhibitor, your company can identify new business leads, market new technology and increase brand awareness, while positioning itself as a thought-leader amongst qualified buyers.
Opportunities include:
Sponsored Presentation Present your scientific research and solutions for 15 or 30 minutes as part of the conference program, ensuring your audience is seated and ready to listen.
Breakfast & Luncheon Presentations
Invite session delegates to enjoy breakfast or lunch on your company's behalf while you give a 30-minute presentation. Your workshop is concluded with 15 minutes of Q&A, allowing you to interact with your customer base.
Exhibitor Information
The exhibit hall presents and excellent opportunity to network with over 120 prominent scientists and executives who attend the event to learn about cutting edge research and technologies in their field. Exhibiting will allow your company to meet hard to reach prospects face to face, and pave the way for future sales. Exhibit space fills up quickly, so reserve yours today! 
